Last updated: September 30, 2026
DAYTRANA is a methylphenidate transdermal system for attention-deficit/hyperactivity disorder, or ADHD, in patients ages 6 to 17. The product received FDA approval in 2006 and created a differentiated delivery option in a market dominated by oral stimulants. Its commercial position weakened after generic methylphenidate patches entered the U.S. market, while supply interruptions, patch-specific tolerability issues, controlled-substance distribution requirements, and broad competition from oral and nonstimulant ADHD therapies limited growth.
Product-level revenue is not separately disclosed in current public filings. DAYTRANA is therefore best assessed as a mature, niche prescription product rather than a major growth asset.
What is DAYTRANA and how does the product work?
DAYTRANA delivers methylphenidate through the skin. The patch is applied to the hip and is worn for a controlled period, allowing patients or caregivers to adjust exposure by changing application time.
| Product attribute |
DAYTRANA position |
| Active ingredient |
Methylphenidate |
| Dosage form |
Transdermal patch |
| FDA application |
NDA 021514 |
| Initial FDA approval |
April 6, 2006 |
| Approved population |
Pediatric patients ages 6 to 17 |
| Strengths |
10 mg, 15 mg, 20 mg, and 30 mg |
| Indication |
ADHD |
| Original developer |
Noven Pharmaceuticals |
| Current commercial category |
Mature branded stimulant with generic competition |
| Regulatory classification |
Schedule II controlled substance |
The system provides an alternative for patients who have difficulty swallowing tablets, need flexible duration, or respond differently to transdermal delivery. The label permits removal before the end of the wear period, although delayed absorption and residual drug exposure must be considered. The product is not interchangeable with oral methylphenidate on a milligram-for-milligram basis because absorption, timing, and exposure differ by route of administration. [1]
What formulations are protected by DAYTRANA?
DAYTRANA’s principal technical differentiation is the transdermal delivery system rather than a new methylphenidate molecule. The commercial formulation combines methylphenidate with a patch system designed to control skin absorption.
Product-specific considerations include:
- Four dosage strengths.
- A transdermal delivery matrix.
- Application to the hip rather than oral administration.
- Wear-time control that can influence duration.
- Skin adhesion, irritation, and handling requirements.
- Controlled-substance manufacturing and distribution controls.
These attributes create formulation and manufacturing know-how, but they do not provide the same long-term protection as composition-of-matter exclusivity. Methylphenidate itself is an established active ingredient with extensive generic competition in oral dosage forms.
When did DAYTRANA lose exclusivity?
DAYTRANA’s core regulatory exclusivity expired years before the current market period. FDA approved the original product in 2006, and the product’s pediatric indication was not protected by the type of new chemical entity exclusivity associated with a newly discovered active ingredient.
A generic methylphenidate transdermal system received FDA approval in 2015. That approval materially changed the product’s competitive position because it established a regulatory pathway for a patch with the same active ingredient and delivery route. [2]
DAYTRANA exclusivity timeline
| Event |
Date or period |
Commercial effect |
| FDA approval of DAYTRANA |
April 2006 |
Established the branded transdermal methylphenidate market |
| Initial pediatric exclusivity period |
Expired after launch-period protection |
Protected the approved pediatric indication for a limited period |
| Historical formulation and delivery patents |
Expired or moved beyond their principal commercial protection period |
Reduced barriers to generic entry |
| First FDA-approved generic patch |
2015 |
Created direct transdermal competition |
| Current position |
Mature market |
Brand depends on physician familiarity, patient response, access, and supply |
The exact Orange Book status should be evaluated using the current FDA Orange Book database because listed patents and pediatric extensions can change over time. The commercial conclusion is stable: DAYTRANA no longer has an effective, long-duration exclusivity barrier comparable to a newly approved innovative drug.
What is the Orange Book status of DAYTRANA?
DAYTRANA is an FDA-approved prescription product with an NDA record and historical patent listings associated with methylphenidate transdermal delivery. The relevant legal protection has centered on the patch system, formulation, and delivery technology rather than methylphenidate’s underlying chemical identity.
The principal patent categories historically associated with the product include:
| Patent category |
Scope |
Strategic relevance |
| Transdermal methylphenidate systems |
Delivery of methylphenidate through skin |
Supported the original product architecture |
| Patch formulation and matrix technology |
Drug loading, adhesive system, and release characteristics |
Could delay or complicate generic development |
| Method-of-use claims |
Treatment of ADHD with transdermal methylphenidate |
Narrower protection than composition-of-matter claims |
| Manufacturing processes |
Patch production, uniformity, adhesion, and release performance |
May create technical barriers without blocking all substitutes |
The Orange Book does not prevent a generic company from developing a different product outside an expired patent claim. Generic applicants can challenge listed patents through Paragraph IV certifications or wait for expiration. Because the main product patents are now historical rather than newly enforceable barriers, patent litigation is unlikely to restore brand-level exclusivity.
Which companies are challenging DAYTRANA, and what is the Paragraph IV risk?
The key competitive event was the development and FDA approval of generic methylphenidate transdermal systems, including an Actavis generic approved in 2015. The generic pathway demonstrated that the FDA considered the patch technology sufficiently reproducible for abbreviated approval. [2]
Paragraph IV risk for DAYTRANA was concentrated around:
- Whether the generic patch infringed listed formulation or delivery patents.
- Whether the patents were valid and enforceable.
- Whether the generic product was bioequivalent or therapeutically equivalent under FDA standards.
- Whether commercial launch could occur before patent expiration or after a litigation settlement.
The principal risk has already materialized through generic approval. The current question is not whether generic entry is possible, but how much prescription volume can be retained by the brand and how consistently generic supply remains available.
Publicly available information does not support treating DAYTRANA as an active, high-value patent litigation asset. No current litigation event is central to the product’s market outlook through the latest broadly available public information.
Are there settlement agreements affecting DAYTRANA?
No settlement agreement should be treated as a current market driver without a specific docket, FDA filing, or company disclosure. Historical patent disputes involving generic entry may have affected launch timing, but the product’s present commercial position is governed primarily by generic availability, payer coverage, and demand rather than by a pending settlement.
How does DAYTRANA compare with competing ADHD drugs?
DAYTRANA competes in a large but fragmented ADHD market. Its direct competitors include oral methylphenidate products, amphetamine stimulants, lisdexamfetamine, atomoxetine, guanfacine, and clonidine.
| Product class |
Examples |
Competitive impact on DAYTRANA |
| Oral methylphenidate |
Ritalin, Concerta, generic immediate- and extended-release products |
Strongest therapeutic substitution risk |
| Amphetamine stimulants |
Adderall, Mydayis, generic mixed amphetamine salts |
Compete for the same stimulant-treated population |
| Lisdexamfetamine |
Vyvanse and generic lisdexamfetamine |
Competes on duration and dosing convenience |
| Nonstimulants |
Strattera, Qelbree, Intuniv |
Relevant where stimulant risks or tolerability concerns limit use |
| Transdermal methylphenidate |
DAYTRANA and generic equivalents |
Direct route-of-administration competition |
DAYTRANA has a differentiated administration route, but the patch also introduces disadvantages. Skin irritation, visible application, adhesion problems, delayed onset, controlled-substance restrictions, and higher product complexity can reduce adoption. Oral products generally have broader prescriber familiarity and more extensive generic supply.
What FDA regulatory issues affect DAYTRANA?
FDA regulation affects DAYTRANA through both stimulant controls and transdermal product requirements.
Controlled-substance requirements
Methylphenidate is a Schedule II controlled substance. Manufacturers, wholesalers, pharmacies, and prescribers operate under DEA rules governing quotas, ordering, recordkeeping, diversion controls, and dispensing. These requirements can amplify supply volatility during periods of stimulant shortages.
Manufacturing and quality requirements
The patch must meet specifications for:
- Drug content uniformity.
- Adhesion.
- Release rate.
- Residual drug content after use.
- Lot-to-lot consistency.
- Skin compatibility.
- Packaging and controlled-substance security.
Manufacturing interruptions can affect a patch product more severely than a conventional tablet because the delivery system contains both a drug formulation and a physical adhesive platform.
FDA shortage and supply exposure
Stimulant shortages have affected multiple methylphenidate and amphetamine products in the United States. DAYTRANA has faced historical availability concerns, and its niche manufacturing base creates concentration risk. A prescriber may switch a patient to an oral methylphenidate or amphetamine product if the patch is unavailable.
How strong is the DAYTRANA patent estate?
DAYTRANA’s patent estate is weak as a current exclusivity platform but still relevant as a historical example of formulation-based protection.
| Patent-estate factor |
Assessment |
| Active ingredient protection |
Weak; methylphenidate is long established |
| Transdermal delivery protection |
Historically meaningful, now substantially eroded |
| Formulation protection |
Moderate historically; limited current blocking value |
| Method-of-use protection |
Narrow and vulnerable to design-around strategies |
| Manufacturing know-how |
Potentially important for quality and supply |
| Biosimilar protection |
Not applicable |
| Current launch-blocking strength |
Low |
The product’s strongest residual barriers are operational rather than legal. A competing company must reproduce a reliable patch, establish bioequivalence or therapeutic equivalence, secure controlled-substance manufacturing capacity, and maintain supply. Those barriers can limit the number of viable competitors, but they do not preserve brand pricing once generic products are approved.
What generic entry risks exist for DAYTRANA?
Generic entry affects DAYTRANA through four channels:
- Price erosion. Payers and pharmacy benefit managers can favor the lower-cost generic patch.
- Formulary substitution. Generic substitution can occur without a new physician decision where state law and product equivalence permit it.
- Prescriber switching. Physicians may select oral generic methylphenidate when patch access is limited.
- Contracting pressure. The brand may require rebates, patient-support programs, or limited-distribution arrangements to retain share.
Generic erosion may be slower than for tablets because transdermal products require specific patient acceptance and pharmacy availability. Some patients remain on DAYTRANA after achieving stable control, particularly where the patch solves adherence or swallowing problems. That persistence does not eliminate the long-term pricing threat.
What is the financial trajectory of DAYTRANA?
Public filings do not separately report current DAYTRANA revenue, gross margin, prescription volume, or operating profit. Noven has historically reported product and corporate performance, while parent-company disclosures have not provided a continuing, standalone DAYTRANA income statement.
The financial trajectory can therefore be characterized by market stage rather than by a verified product revenue series.
Financial development by stage
| Period |
Financial profile |
| 2006 to early commercialization |
Investment phase, including launch, physician education, manufacturing scale-up, and controlled-substance distribution |
| Expansion period |
Niche growth driven by patients seeking nonoral methylphenidate delivery |
| Generic-entry period |
Pricing and volume pressure after FDA approval of generic transdermal methylphenidate |
| Mature period |
Lower growth, limited pricing power, and revenue dependence on brand retention |
| Current outlook |
Stable or declining revenue unless supply advantages, contracting, or patient-support programs offset generic erosion |
DAYTRANA is unlikely to be a material growth driver for a large pharmaceutical company. Its value is more likely to reside in:
- Incremental cash flow from a recognized brand.
- A differentiated delivery option for selected patients.
- Manufacturing know-how in transdermal drug delivery.
- Commercial relationships with pediatric ADHD prescribers.
- Potential portfolio fit with other CNS or patch products.
How does DAYTRANA compare with other transdermal drug products?
DAYTRANA’s commercial logic resembles other specialty patches: the route can support adherence and controlled exposure, but product success depends on reliable adhesion, skin tolerability, and manufacturing consistency.
Compared with oral products, DAYTRANA has:
- A narrower patient segment.
- Higher manufacturing complexity.
- Greater physical-product failure points.
- More visible administration.
- Potential adherence advantages.
- Less straightforward substitution across dosage strengths.
Compared with nonstimulant ADHD therapies, DAYTRANA has the efficacy profile and abuse-related constraints associated with a Schedule II stimulant. It may be clinically attractive for some patients but is not a broad replacement for nonstimulants.
What is the geographic coverage and international opportunity?
DAYTRANA’s principal commercial relevance is in the United States. The product’s FDA approval, U.S. controlled-substance framework, and U.S.-specific generic pathway define its largest identifiable market.
International expansion faces several constraints:
- Different regulatory requirements for methylphenidate.
- National controlled-substance restrictions.
- Reimbursement differences.
- Local competition from oral formulations.
- Need for country-specific patch approvals and supply chains.
- Limited commercial rationale for expanding a mature product with generic competition.
The international opportunity is therefore limited unless a company has existing CNS infrastructure and a low-cost regulatory strategy.
What licensing deals affect DAYTRANA?
Noven Pharmaceuticals developed DAYTRANA and was acquired by Hisamitsu Pharmaceutical in 2009. The transaction gave Hisamitsu access to Noven’s transdermal delivery capabilities and U.S. pharmaceutical portfolio. [3]
The strategic value of the transaction extended beyond a single ADHD product. Hisamitsu’s broader business is associated with topical and transdermal products, making DAYTRANA relevant as part of a delivery-technology portfolio.
No current licensing transaction publicly changes DAYTRANA’s competitive position. The product is better analyzed as an established asset within a broader corporate portfolio than as a standalone partnered innovation.
What generic launch scenarios are most likely?
Base case
Generic methylphenidate patches maintain market access, while DAYTRANA retains a smaller premium segment based on prescriber familiarity, patient stability, and perceived consistency. Revenue declines gradually rather than collapsing immediately.
Downside case
Generic supply improves, payer substitution increases, and patients shift to lower-cost oral methylphenidate. DAYTRANA becomes a low-volume product with limited pricing power.
Supportive case
Generic patch supply remains inconsistent, patients value the branded product’s reliability, and manufacturers preserve access through targeted contracting. DAYTRANA retains a meaningful niche despite lower overall market share.
The most likely outcome is continued niche use with limited revenue growth. A major rebound would require a new clinical positioning, supply advantage, or commercial strategy.
Key Takeaways
- DAYTRANA is a mature transdermal methylphenidate product approved by the FDA in 2006.
- Its differentiation is the delivery system, not a new active ingredient.
- Generic methylphenidate transdermal competition entered the U.S. market in 2015.
- The current patent estate has low practical blocking strength compared with an active composition-of-matter estate.
- Biosimilar risk is irrelevant because DAYTRANA is a small-molecule drug, not a biologic.
- The largest commercial risks are generic substitution, oral stimulant competition, supply interruptions, and patch-specific tolerability issues.
- Product-level revenue is not separately disclosed, preventing a verified current sales or profit series.
- DAYTRANA is best classified as a mature, defensible niche asset rather than a growth product.
- Operational execution, manufacturing reliability, payer access, and patient persistence matter more than new patent exclusivity.
Frequently Asked Questions
Is DAYTRANA still FDA approved?
Yes. DAYTRANA remains an FDA-approved transdermal methylphenidate product for ADHD in pediatric patients ages 6 to 17, subject to current labeling and commercial availability. [1]
Is DAYTRANA interchangeable with Concerta or Ritalin?
No. DAYTRANA is not automatically interchangeable with oral methylphenidate products because the route, absorption profile, onset, duration, and dose conversion differ.
Does DAYTRANA have biosimilar competition?
No. Biosimilar rules apply to biologics. DAYTRANA is a small-molecule methylphenidate product and faces generic-drug competition instead.
Who owns DAYTRANA?
Noven Pharmaceuticals developed the product, and Noven became part of Hisamitsu Pharmaceutical following Hisamitsu’s acquisition of Noven. Commercial arrangements and product-label ownership should be checked against the current FDA application record.
Is DAYTRANA a high-growth pharmaceutical asset?
No. DAYTRANA is a mature niche product with generic competition, limited disclosed financial growth, and a market dependent on selected patients who prefer transdermal methylphenidate.
References
-
U.S. Food and Drug Administration. (2006). DAYTRANA (methylphenidate transdermal system) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2015). FDA approves first generic version of Daytrana. FDA.
-
Hisamitsu Pharmaceutical Co., Inc. (2009). Acquisition of Noven Pharmaceuticals, Inc. Company disclosure.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
